GlobeNewswire

Kemira provides an outlook for H2 2020: Operative EBITDA in H2 2020 expected to be lower than in H1 2020

Share

Kemira Oyj
Inside information
July 17, 2020 at 8.30 am (CET+1)

Kemira provides an outlook for H2 2020: Operative EBITDA in H2 2020 expected to be lower than in H1 2020


In conjunction with its Half-Year Financial Report for 2020 published today July 17, 2020, Kemira provided an outlook for the second half of 2020.

OUTLOOK FOR JULY-DECEMBER 2020
Operative EBITDA in H2 2020 is expected to be lower than in H1 2020 (H1 2020: EUR 214 million).

Assumptions behind Kemira's outlook for July-December 2020:
Overall demand in Kemira's end markets in H2 2020 is expected to be approximately at the same level as in Q2 2020. Demand in Pulp & Paper is expected to remain approximately at the Q2 2020 level, with printing and writing demand to remain weak. Also in Industry & Water, demand is expected to remain approximately at the Q2 2020 level. The shale market is not anticipated to recover in 2020.

Kemira's outlook for H2 2020 assumes no significant disruptions to Kemira's manufacturing operations or supply chain.

Previous outlook (published April 27, 2020):
On April 27, 2020, Kemira withdrew its outlook for 2020 due to the uncertainty following the COVID-19 pandemic and the oil price drop.

For more information, please contact:

Kemira Oyj
Mikko Pohjala, Vice President, Investor Relations
Tel. +358 40 838 0709

Kemira is a global chemicals company serving customers in water intensive industries. We provide best suited products and expertise to improve our customers’ product quality, process and resource efficiency. Our focus is on pulp & paper, oil & gas and water treatment. In 2019, Kemira had annual revenue of around EUR 2.7 billion and over 5,000 employees. Kemira shares are listed on the Nasdaq Helsinki Ltd.
www.kemira.com

About GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire

Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire

Scandinavian Tobacco Group A/S: Transactions in connection with share buy-back programme21.9.2020 10:00:00 CESTPress release

Company Announcement No. 28/2020 Copenhagen, 21 September 2020 Transactions in connection with share buy-back programme On 28 August 2020, Scandinavian Tobacco Group A/S (“STG”) announced that a share buy-back programme of an aggregated price of up to DKK 300 million was launched with the purpose to adjust the Company’s capital structure and meet obligations relating to the Group’s share-based incentive programme. The buy-back programme is executed in accordance with Regulation No. 596/2014 of the European Parliament and Council of 16 April 2014 (the “Market Abuse Regulation”) and Commission Delegated Regulation (EU) 2016/1052, also referred to as the Safe Harbour rules. The share buy-back programme will end no later than 26 February 2021. The following transactions have been executed from 14 September to 18 September 2020: Number of sharesAverage purchase price, DKKTransaction value, DKK Accumulated, last announcement 283,320 28,190,854 14 September 2020 25,000 94.39 2,359,713 15 Sept

Scandinavian Tobacco Group A/S: Transaktioner i forbindelse med aktietilbagekøbsprogram21.9.2020 10:00:00 CESTpressemeddelelse

Selskabsmeddelelse Nr. 28/2020 København, 21. september 2020 Transaktioner i forbindelse med aktietilbagekøbsprogram Den 28. august 2020 informerede Scandinavian Tobacco Group A/S (“STG”) om iværksættelsen af et aktietilbagekøbsprogram til en samlet pris på op til DKK 300 millioner med det formål at justere selskabets kapitalstruktur og opfylde forpligtelserne i forhold til koncernens aktiebaserede incitamentsprogram. Aktietilbagekøbsprogrammet vil blive gennemført i overensstemmelse med EU-forordning nr. 596/2014 af 16. april 2014 (Markedsmisbrugsforordningen) og Kommissionens delegerede forordning (EU) 2016/1052, de såkaldte Safe Harbour-regler. Aktietilbagekøbsprogrammet slutter senest den 26. februar 2021. Følgende transaktioner er foretaget i perioden 14. september - 18. september 2020: Antal aktierGennemsnitlig købspris, DKKTransaktionsværdi, DKK Total, seneste opgørelse 283.320 28.190.854 14. september 2020 25.000 94.39 2.359.713 15. september 2020 25.000 94.50 2.362.538 16. sep

Press Release Oncology Venture Plans Name Change to Allarity Therapeutics and Board Restructuring to Align with Current Company Strategy21.9.2020 09:36:27 CESTPress release

Hørsholm, Denmark (21 September 2020) – Oncology Venture A/S (“OV”) today announced that it will change its company name to Allarity Therapeutics (“Allarity” or the “Company”) and will significantly restructure its Board of Directors to align with the company’s current and long-term strategy. Both the proposed name change and appointment of new Board members are subject to approval of shareholders at the upcoming Extraordinary General Meeting (EGM) planned to be convened on 7 October 2020. Following the proposed restructuring, Allarity’s Board of Directors will comprise five members, including existing Directors Mr. Steve Carchedi (CEO), Mr. Duncan Moore (Chairman), and Dr. Magnus Persson, and new members in both the U.S. and Scandinavia, including Mr. Søren Gade (a current member of European Parliament and former Minister of Defense in Denmark) and Ms. Gail Maderis (current CEO of Antiva Biosciences, Inc., Board member of Valitor, Inc., and former CEO of Five Prime Therapeutics, Inc.)

Immunicum AB: Invitation to Corporate Update Event21.9.2020 08:50:00 CESTPress release

Press Release 21 September 2020 Immunicum AB: Invitation to Corporate Update Event Immunicum AB (publ: IMMU.ST) announced today that the Company will hold a corporate update event and live webcast on September 30, 2020. Investors, media and the public are welcome to join. During the event, CEO, Sven Rohmann, COO, Sijme Zeilemaker and CSO, Alex Karlsson-Parra will present an overview of Immunicum and its development priorities. Corporate Update Event Information Date: Wednesday, September 30, 2020 Time: 18.00 – 19.30 CEST The event will be livestreamed and will remain accessible in video format following the completion of the event. The link to the livestream is available here: https://www.redeye.se/events/793598/live-strategy-update-immunicum Questions can be asked prior to the event by sending an e-mail to ir@immunicum.com or through the video chat during the webcast. Preliminary Agenda: 18:00 – 18:15 Welcome 18:15 – 18:30 The exciting potential of ilixadencel and beyond 18:30 – 18:45

Immunicum AB: inbjudan till företagspresentation21.9.2020 08:50:00 CESTPressemelding

Pressmeddelande 21 september 2020 Immunicum AB: inbjudan till företagspresentation Immunicum AB (publ; IMMU.ST) meddelar idag att företaget kommer att hålla en livesänd företagspresentation den 30 september 2020. Investerare, media och allmänheten välkomnas att delta. Under evenemanget kommer VD Sven Rohmann, COO Sijme Zeilemaker och forskningschef Alex Karlsson-Parra att presentera en bolagsöversikt och prioriteringar för bolagets fortsatta utveckling. Information om företagspresentationen Datum: onsdagen den 30 september 2020 Tid: 18.00 - 19.30 CET Presentationen kommer att webbsändas och kommer även att finnas tillgänglig i efterhand. Länken till webbsändningen finns här: https://www.redeye.se/events/793598/live-strategy-update-immunicum Frågor kan ställas före evenemanget genom att skicka ett e-postmeddelande till ir@immunicum.com eller via videochatten under webbsändningen. Preliminär agenda: 18:00 - 18:15 Välkomnande 18:15 - 18:30 Ilixadencels potential och framtid 18:30 - 18:45

Participation Notification by Blackrock Inc.21.9.2020 08:30:00 CESTPress release

Participation notification by Blackrock Inc. Brussels, September 21, 2020, 08:30 CEST - According to Belgian transparency legislation (Law of May 2, 2007), BlackRock Inc. (55 East 52nd Street, New York, NY, 10055, U.S.A.) recently sent to Solvay the following transparency notifications indicating that it crossed the threshold of 3%. Here is a summary of the moves: Date on which the threshold was crossedVoting rights after the transactionEquivalent financial instruments after the transactionTotalSeptember 15, 20203.05%0.11%3.16%September 17, 20202.88%0.16%3.14% The latest notification, dated September 18, 2020, contains the following information: Reason for the notification: acquisition or disposal of voting securities or voting rightsNotified by: BlackRock Inc. (55 East 52nd Street, New York, NY, 10055, U.S.A.)Date on which the threshold is crossed: September 17, 2020Threshold of direct voting rights crossed: 3% downwardsDenominator: 105,876,416Additional information: The disclosure ob